Syndax Pharmaceuticals, Inc. (SNDX) is a biopharmaceutical company developing innovative pipeline therapies for cancer patients. One of the candidate products of the company is SNDX-5613 which is phase 1/2 trial used for the treatment of acute myeloid leukemia more specifically NPM1c AML. Another lead product is SNDX-6352 or axatilimab used for the treatment of chronic graft versus host disease.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The price of SNDX stock ended the regular trading session of December 15, 2021 at $18.97 with a gain of 6.69%. At last check in the after market session, the stock declined significantly by 11.70%.
Events and Happenings
On December 15, 2021, SNDX reported about its plan to offer and sell shares of its common stock in an underwritten public offering. Syndax may, instead of common stock, offer and sell pre-funded warrants to certain investors to purchase shares of its common stock in the underwritten public offering.
On December 13, 2021, SNDX reported positive results from the Phase 1 trial of the AUGMENT-101 of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemia. The findings were presented at the 63rd American Society of Hematology (ASH) Annual Meeting on Monday, December 13, 2021.
On December 11, 2021, SNDX reported positive results from Phase 1/2 trial of axatilimab in recurrent or refractory chronic graft-versus-host disease (cGVHD) patients. The findings were presented at the 63rd ASH Annual Meeting on Saturday, December 11, 2021.
On December 9, 2021, SNDX announced that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties locked the exclusive worldwide partnership and license collaboration between SNDX and Incyte for the development and commercialization of axatilimab. In this regard, Incyte paid SNDX the $117 million preliminary license fee, and Syndax finalized Incyte’s $35 million equity investment in the company.
On November 15, 2021, SNDX announced financial results for its third quarter ended September 30, 2021. Some of the key highlights are as follows
Net loss per Share
For the third quarter of 2021, net loss of $20.6 million or $0.40 per basic and diluted share was reported in comparison to $20.4 million or $0.46 per basic and diluted share for the prior year period.
The total assets reported by SNDX during Q3 2020 were $179 million versus the total assets of $239 million for Q3 2021.
The current decline in the stock of SNDX can be attributed to public offering of its common stock. The company is mostly showing positive results in the oncology related trials, the investors are optimistic about the company’s stock to rise.